Related Experiment Video

Updated: Aug 9, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients

M A Kuiper1, C H Konings, P L Bergmans

  • 1Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.

Journal of the Neurological Sciences
|July 1, 1993
PubMed

Insights

Monoamine oxidase B (MAO-B) activity in whole blood did not differ between Parkinson's disease patients and controls. This suggests MAO-B levels are not a reliable biomarker for Parkinson's disease diagnosis or progression.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Medical Research

Background:

  • Monoamine oxidase type B (MAO-B) breaks down dopamine (DA) in the brain.
  • MAO-B is implicated in Parkinson's disease (PD) pathophysiology.
  • Previous studies on MAO-B activity in PD platelets yielded conflicting results.

Purpose of the Study:

  • To investigate MAO activity in whole blood as a proxy for platelet MAO-B in Parkinson's disease.
  • To compare MAO activity across drug-naive PD patients, treated PD patients, multiple system atrophy (MSA) patients, and controls.
  • To assess the correlation between MAO activity and PD severity or duration.

Main Methods:

  • A spectrofluorimetric method using kynuramin as a substrate was employed.
  • MAO activity was measured in whole blood samples.
  • Participants included 25 drug-naive PD patients, 25 treated PD patients, 9 MSA patients, and 20 controls.

Main Results:

  • No statistically significant differences in MAO activity were observed between the studied groups (PD, MSA, controls).
  • MAO activity did not correlate with the severity or duration of Parkinson's disease.
  • Whole blood MAO activity serves as a reliable indicator of platelet MAO-B activity.

Conclusions:

  • MAO activity in whole blood is not significantly different in Parkinson's disease patients compared to controls or MSA patients.
  • MAO activity does not appear to be a useful biomarker for diagnosing Parkinson's disease or monitoring its progression.
  • Further research may be needed to explore other potential biomarkers for Parkinson's disease.

More Related Videos

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model06:07

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

Published on: June 23, 2023

Related Concept Videos

Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...